A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

Background: Two aldosterone inhibitors are currently licensed for heart failure (HF) in the UK: spironolactone and eplerenone. Recent clinical guidelines recommend eplerenone after an acute myocardial infarction (MI) for patients with symptoms and/or signs of HF and left ventricular dysfunction. Obj...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: C McKenna, J Burch, S Suekarran, S Walker, A Bakhai, K Witte, M Harden, K Wright, N Woolacott, P Lorgelly, L Fenwick, S Palmer
Формат: Artigo
Язык:Inglês
Опубликовано: NIHR Journals Library 2010-05-01
Серии:Health Technology Assessment
Предметы:
aldosterone-antagonists
eplerenone
heart-failure
myocardial-infarction
spironolactone
Online-ссылка:https://doi.org/10.3310/hta14240
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы